Whole cell vaccines--past progress and future strategies.
about
Safety of targeting tumor endothelial cell antigensRecent advances in the development of breast cancer vaccines.Current status of autologous breast tumor cell-based vaccines.Development of Membrane-Bound GM-CSF and IL-18 as an Effective Tumor Vaccine.Branched Polyethylenimine-Superparamagnetic Iron Oxide Nanoparticles (bPEI-SPIONs) Improve the Immunogenicity of Tumor Antigens and Enhance Th1 Polarization of Dendritic CellsAutologous tumor lysate/Bacillus Calmette-Guérin immunotherapy as an adjuvant to conventional breast cancer therapyInjectable cryogel-based whole-cell cancer vaccines.Vaccination with tumor cells expressing IL-15 and IL-15Rα inhibits murine breast and prostate cancer.The potential role of immunotherapy to treat colorectal cancer.Immunology of chronic myeloid leukemia: current concepts and future goals.Generation of potent cytotoxic T lymphocytes against in male patients with non-muscle invasive bladder cancer by dendritic cells loaded with dying T24 bladder cancer cells.Irradiated tumor cells of lipopolysaccharide stimulation elicit an enhanced anti-tumor immunity.Recent progress in immunotherapy for urological cancer.Immunotherapy of cancers comes of age.Dendritic cell-based autologous tumor vaccines for head and neck squamous cell carcinoma.Polyelectrolyte-Enrobed Cancer Cells in View of Personalized Immune-TherapyNanoparticulate Delivery of Cancer Cell Membrane Elicits Multiantigenic Antitumor Immunity.Whole-Cell Cancer Vaccines Induce Large Antibody Responses to Carbohydrates and Glycoproteins.Heating up cancer vaccines.Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases.Targeting Head and Neck Cancer by Vaccination.SV-BR-1-GM, a Clinically Effective GM-CSF-Secreting Breast Cancer Cell Line, Expresses an Immune Signature and Directly Activates CD4+ T Lymphocytes.Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy.Breast cancer vaccination comes to age: impacts of bioinformatics
P2860
Q26748863-264AD16D-7158-4FE3-A2FB-68EE82B5E874Q34379303-9860995A-840E-4F56-A525-1712B110725FQ35154214-3B993274-BB95-4B6E-9A3B-FCFC2779280AQ35695115-19042360-60BA-4B78-A531-DBC4E89B183DQ35843258-69207068-1F75-4814-B665-5818DB72678DQ36171703-8F0E01BC-B106-44BE-97EC-35057FCC29C0Q36608119-5DCF054E-C0E7-4B71-BB49-66DE91F16244Q37685855-94FE45BD-7A0D-44C7-81FC-8A68B2B874FCQ38292169-EE5DE5BF-2374-41B1-BC77-69F7DECB014EQ38366539-3B861BF2-BC6A-4B67-992A-3EA988A71E8BQ38713382-ABF211F9-8694-4357-A4A2-BCDD648D94A5Q38985050-3065C0F2-9FA5-4B15-BCFE-6DF186491014Q39388043-AE81FACF-4D4E-4F84-9CF3-4F936D8C8C29Q40099075-2D0F97AF-4CFD-44CE-990E-8D8E823921D4Q41237376-8FB41B7A-F5CE-4A08-A62C-58A1D4B36684Q42199258-549E2245-FF41-480C-B30D-DB3C41550DEEQ46064523-23E0D6C2-23F6-44A3-A5C4-E556D72971ECQ46767596-569AC821-E430-48A6-A986-52569C966255Q48323706-E871D8C7-2985-4D3D-8B09-07CBCF210DA9Q50115667-73334B0D-017D-42D8-A3AF-12A3B152DB8EQ54217605-1D1158D9-3A13-4962-9B8F-C5737B7D83F9Q55342016-A47B4399-A812-45D5-BC6E-255C74C610A3Q55386489-270C4C47-FCF7-4C09-A131-85157998EB9FQ57114951-3C1DF84A-1A57-4D16-B993-76BDD0C92063
P2860
Whole cell vaccines--past progress and future strategies.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Whole cell vaccines--past progress and future strategies.
@ast
Whole cell vaccines--past progress and future strategies.
@en
type
label
Whole cell vaccines--past progress and future strategies.
@ast
Whole cell vaccines--past progress and future strategies.
@en
prefLabel
Whole cell vaccines--past progress and future strategies.
@ast
Whole cell vaccines--past progress and future strategies.
@en
P2860
P1433
P1476
Whole cell vaccines--past progress and future strategies.
@en
P2093
Bridget P Keenan
P2860
P304
P356
10.1053/J.SEMINONCOL.2012.02.007
P577
2012-06-01T00:00:00Z